CYTOKINES, SEPSIS AND IMMUNOMODULATION

被引:203
作者
MOLLOY, RG
MANNICK, JA
RODRICK, ML
机构
[1] BRIGHAM & WOMENS HOSP,BOSTON,MA 02115
[2] HARVARD UNIV,SCH MED,DEPT SURG IMMUNOL,BOSTON,MA 02115
关键词
D O I
10.1002/bjs.1800800308
中图分类号
R61 [外科手术学];
学科分类号
摘要
Tissue injury and infection produce significant alterations in host metabolic and immune homoeostasis. It is increasingly clear that many of these changes result from a complex cascade of mononuclear phagocyte-derived endogenous mediators. Among the more important is a group of host proteins called cytokines, which play an integral role in mediating the host response to tissue injury and infection. Of these proteins, tumour necrosis factor (TNF) and interleukin (IL) types 1 and 6 have received much attention for their pathophysiological roles in infection and trauma. Evidence is reviewed for the involvement of these cytokines in the characteristic alterations in the metabolic and immune responses to such injury. These endogenous mediators initiate an integrated fuel substrate and hormonal adjustment to trauma and sepsis, and help to provide optimal metabolic homoeostasis for systemic host defences. Widespread tissue injury, especially when associated with fulminant sepsis, may, however, precipitate massive release of TNF, IL-1 and IL-6, triggering a series of reactions involving multiple organs, and culminating in the 'sepsis syndrome'. New therapies designed to downregulate this aberrant response, either by neutralizing endotoxin directly or by blocking the release or actions of these cytokines, are reviewed. Although these treatments hold much promise for the future management of severely traumatized and infected patients, careful evaluation of both the benefits and complications of therapy is needed before widespread clinical use can be recommended.
引用
收藏
页码:289 / 297
页数:9
相关论文
共 143 条
[1]  
ABRAHAM E, 1988, CIRC SHOCK, V25, P33
[2]   CHARACTERIZATION OF RECEPTORS FOR HUMAN-TUMOR NECROSIS FACTOR AND THEIR REGULATION BY GAMMA-INTERFERON [J].
AGGARWAL, BB ;
EESSALU, TE ;
HASS, PE .
NATURE, 1985, 318 (6047) :665-667
[3]   A RECOMBINANT HUMAN RECEPTOR ANTAGONIST TO INTERLEUKIN-1 IMPROVES SURVIVAL AFTER LETHAL ENDOTOXEMIA IN MICE [J].
ALEXANDER, HR ;
DOHERTY, GM ;
BURESH, CM ;
VENZON, DJ ;
NORTON, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (04) :1029-1032
[4]   INTERLEUKIN-1 RECEPTOR ANTAGONIST - A NEW MEMBER OF THE INTERLEUKIN-1 FAMILY [J].
AREND, WP .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (05) :1445-1451
[5]   TUMOR-NECROSIS-FACTOR STIMULATES INTERLEUKIN-1 AND PROSTAGLANDIN-E2 PRODUCTION IN RESTING MACROPHAGES [J].
BACHWICH, PR ;
CHENSUE, SW ;
LARRICK, JW ;
KUNKEL, SL .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1986, 136 (01) :94-101
[6]  
BAGLIONI C, 1985, J BIOL CHEM, V260, P3395
[7]  
BAUMGARTNER JD, 1985, LANCET, V2, P59
[8]   RAPID RELEASE OF MULTIPLE HORMONES FROM RAT PITUITARIES PERIFUSED WITH RECOMBINANT INTERLEUKIN-1 [J].
BEACH, JE ;
SMALLRIDGE, RC ;
KINZER, CA ;
BERNTON, EW ;
HOLADAY, JW ;
FEIN, HG .
LIFE SCIENCES, 1989, 44 (01) :1-7
[9]  
BEUSCHER HU, 1987, J IMMUNOL, V139, P1896
[10]   PURIFICATION OF CACHECTIN, A LIPOPROTEIN-LIPASE SUPPRESSING HORMONE SECRETED BY ENDOTOXIN-INDUCED RAW 264.7 CELLS [J].
BEUTLER, B ;
MAHONEY, J ;
LETRANG, N ;
PEKALA, P ;
CERAMI, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1985, 161 (05) :984-995